Information Provided By:
Fly News Breaks for September 29, 2015
ESPR
Sep 29, 2015 | 09:14 EDT
After Esperion commented on the FDA minutes from a Phase II meeting, Stifel says that the FDA has "left the door open" to approve Esperion;s ETC-1002 drug for "truly statin intolerant patients." The firm says that the potential market for the drug has increased by 40%. It keeps a Buy rating on the shares.
News For ESPR From the Last 2 Days
ESPR
Mar 27, 2024 | 10:47 EDT
These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: Altamira Therapeutics... To see the rest of the story go to thefly.com. See Story Here